| 2.44 0.12 (5.17%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.08 | 1-year : | 3.73 |
| Resists | First : | 2.63 | Second : | 3.2 |
| Pivot price | 2.7 |
|||
| Supports | First : | 1.73 | Second : | 1.43 |
| MAs | MA(5) : | 2.62  |
MA(20) : | 2.48 |
| MA(100) : | 2.36 |
MA(250) : | 2.68 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 57.5 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 6.15 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCDA ] has closed above bottom band by 21.9%. Bollinger Bands are 17.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.44 - 2.46 | 2.46 - 2.47 |
| Low: | 2.28 - 2.3 | 2.3 - 2.31 |
| Close: | 2.42 - 2.44 | 2.44 - 2.47 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Fri, 16 May 2025
BioCardia, Inc. (NASDAQ:BCDA) Q1 2025 Earnings Call Transcript - Insider Monkey
Thu, 15 May 2025
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - Yahoo
Wed, 14 May 2025
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - Yahoo Finance
Wed, 14 May 2025
BioCardia Reports Groundbreaking Heart Failure Trial Results: 82% Reduction in Angina Episodes - Stock Titan
Wed, 14 May 2025
BCDA - Biocardia Inc Latest Stock News & Market Updates - Stock Titan
Fri, 09 May 2025
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.49e+006 (%) |
| Held by Institutions | 23.9 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.93e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 794.8 % |
| Return on Equity (ttm) | -149.1 % |
| Qtrly Rev. Growth | 58000 % |
| Gross Profit (p.s.) | -109.9 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.75824e+006 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 12.33 |
| Dividend | 0 |
| Forward Dividend | 137000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|